

# The Bulletin

This monthly bulletin includes recent changes to our medical policies and reimbursement policies. It is a supplement to our bimonthly provider newsletter, [\*The Connection\*](#). **Note:** Medication and dental policy updates are published in *The Connection*.

## Medical policies

### Commercial

#### Changes effective September 1, 2023

##### Genetic Testing

- Evaluating the Utility of Genetic Panels (#64)
  - Added 16 investigational panels
  - Removed 19 panel tests

##### Laboratory

- Laboratory Tests for Organ Transplant Rejection (#51)
  - Added medically necessary criteria for AlloMap test
  - Added investigational criterion for gene expression profiling tests on biopsy tissue (e.g., Molecular Microscope<sup>®</sup> Diagnostic System)

##### Surgery

- Rhinoplasty (#12.28)
  - Added criteria for rhinophyma
- Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy for Tumors Outside of Intracranial, Skull Base, or Orbital Sites (#214)
  - Simplified policy criteria without change to policy intent

#### Changes effective December 1, 2023

##### Surgery

- Cochlear Implants (#08)
  - Added criteria for single-sided deafness
- Ventral (including incisional) Hernia Repair (#12.03)
  - Updating medical policy criteria notes to reflect new coding rules
  - Clarifying documentation in the list of information needed for review

[View our commercial  
Medical Policy Manual](#)

## Medicare Advantage

**Changes effective September 1, 2023**

### Genetic Testing

- Genetic and Molecular Diagnostics – Next Generation Sequencing, Genetic Panels, and Biomarker Testing (#64)
  - Updated Medicare guidance and links, where appropriate

**Changes effective December 1, 2023**

### Medicine

- Intensity Modulated Radiation Therapy (IMRT) (#136)
  - Updating policy criteria because local coverage determination (LCD) L34080 has been retired; criteria will point to the following commercial policies:
    - *Intensity Modulated Radiotherapy (IMRT) for Breast Cancer* (Medicine #166)
    - *Intensity Modulated Radiotherapy (IMRT) for Tumors in Close Proximity to Organs at Risk* (Medicine #167)
    - *Intensity Modulated Radiotherapy (IMRT) of the Central Nervous System (CNS), Head, Neck, and Thyroid* (Medicine #164)
    - *Intensity Modulated Radiotherapy (IMRT) of the Thorax, Abdomen, Pelvis, and Extremities* (Medicine #165)

[View our Medicare Advantage  
Medical Policy Manual](#)

### Join our medical policy discussion

We welcome your input and feedback as we draft our medical policies. [Join our email reviewer list](#). While we prefer to receive input as policies are developed, we also have a formal process that allows you to submit additional information, such as clinical trial results, that may warrant a policy review.

### Recent updates and archived medical policies

[Recent updates and archived medical policies](#) may include revisions that will be published in the next issue of *The Bulletin*.

# Reimbursement policies

There were no recent commercial or Medicare Advantage reimbursement policy updates.

[View our Reimbursement Policy Manual](#)

## Join our reimbursement policy discussion

Comments from physicians and other health care professionals regarding reimbursement policies are welcome. If you have a comment regarding a reimbursement policy, please complete the [Reimbursement Policy Feedback Form](#).

## Verify your provider information

Providing up-to-date and accurate information about the providers in each of our networks is critical for our members to access care and a compliance requirement for the Affordable Care Act (ACA) and Medicare Advantage plans.

## Validating provider directory content

Please [follow these steps](#) to review the information about your practice every 90 days. **Please respond timely to any requests from us for verification of your directory data.**

If your clinic or facility submits provider rosters to us, please submit changes, corrections, additions or terminations immediately so we can update our directories as soon as possible. **Your roster must be validated and reviewed in its entirety at least once per quarter.**

We appreciate your assistance in keeping information about your practice up to date.